Abstract
Immunogenicity following inactivated SARS-CoV-2 vaccination among solid organ transplant recipients has not been assessed. Seventy-five patients (37 kidney transplant [KT] recipients and 38 non-transplant controls) received two doses, at 4-week intervals, of an inactivated whole-virus SARS-CoV-2 vaccine. SARS-CoV-2-specific humoral (HMI) and cell-mediated immunity (CMI) were measured before, 4 weeks post-first dose, and 2 weeks post-second dose. The median age of KT recipients was 50 years (IQR, 42–54) and 89% were receiving calcineurin inhibitors/mycophenolate/corticosteroid regimens. The median time since transplant was 4.5 years (IQR, 2–9.5). Among 35 KT patients, anti-RBD IgG titer after vaccination was not significantly different to baseline, but was significantly lower than in controls (7.8 [95%CI 0.2–15.5] vs 2,691 [95%CI 1,581–3,802], p<0.001) as well as the percentage of surrogate virus neutralizing antibody inhibition (2 [95% CI −1-6] vs 71 [95%CI 61–81], p<0.001). However, the mean of SARS-CoV-2 mixed peptides-specific T-cell responses measured by enzyme-linked immunospot assays was significantly increased compared with baseline (66 [95%CI 36–99] vs. 34 [95%CI 19–50] T-cells/106 PBMCs, p=0.02) and comparable to that in controls. Our findings revealed weak HMI and marginal CMI responses in fully vaccinated KT recipients receiving inactivated SARS-CoV-2 vaccine. (Thai Clinical Trials Registry, TCTR20210226002).
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
Thai Clinical Trials Registry, TCTR20210226002.
Funding Statement
This study received a grant from the National Research Council of Thailand (NRCT), Ministry of Higher Education, Science, Research, and Innovation of Thailand in collaboration with the Department of Medical Services, Ministry of Public Health of Thailand (102912).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All patients provided written consent. The Institutional Review Board of the Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand, reviewed and approved the study protocol (approval number: MURA2021/242).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data will be made available upon appropriate request.
Abbreviations
- ACE2
- angiotensin-converting enzyme 2
- AE
- adverse events
- CI
- confidence interval
- CMI
- SARS-CoV-2-specific cell-mediated immunity
- COVID-19
- coronavirus disease 2019
- ELISpot
- enzyme-linked immunospot assay
- HMI
- SARS-CoV-2-specific humoral immunity
- IFN-γ
- interferon-γ
- IgG
- immunoglobulin G
- IQR
- interquartile range
- KT
- kidney transplant
- M
- SARS-CoV-2 membrane protein
- mRNA
- messenger ribonucleic acid
- N
- SARS-CoV-2 nucleoprotein
- ORF
- open reading frame
- PBMC
- peripheral blood mononuclear cell
- RBD
- receptor binding domain
- RT-PCR
- reverse-transcription polymerase chain reaction
- S
- SARS-CoV-2 spike glycoprotein
- SARS-CoV-2
- severe acute respiratory syndrome coronavirus 2 SFU spot forming units
- SMNO
- SARS-CoV-2 spike protein, nucleoprotein, membrane protein and ORF-3a, and ORF-7a proteins
- SOT
- solid organ transplantation
- sVNT
- SARS-CoV-2 surrogate virus neutralization test
